Quantcast

Pluristem Therapeutics (PSTI) Shares March Higher, Can It Continue?


Shutterstock photo

As of late, it has definitely been a great time to be an investor in Pluristem Therapeutics Inc. PSTI . The stock has moved higher by 25.6% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider PSTI's recent earnings estimate revision activity. From this look, the company's future is quite favorable; as PSTI has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Now See Our Private Investment Ideas

While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum  . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pluristem Therapeutics, Inc. (PSTI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Investing Ideas , Stocks
Referenced Symbols: PSTI



More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research










Research Brokers before you trade

Want to trade FX?